Golar LNG Ltd.’s floating LNG (FLNG) vessel Gimi has received feedgas from a BP-operated FPSO on the Greater Tortue Ahmeyim (GTA) project offshore Mauritania and Senegal. BP said it began flowing gas ...

Golar LNG’s floating LNG production unit Gimi has received its first feed gas from BP’s Greater Tortue Ahmeyim (GTA ... wells into the FPSO for GTA Phase 1. The project comprises an FPSO ...

Golar LNG Limited (“Golar”) is pleased to announce that on January 18, 2025, FLNG Gimi received feed gas from the bp operated FPSO on the Greater Tortue Ahmeyim (“GTA”) project offshore ...

Golar LNG Limited (“Golar”) is pleased to announce that on January 18, 2025, FLNG Gimi received feed gas from the bp operated FPSO on the Greater Tortue Ahmeyim (“GTA”) project offshore Mauritania and ...

Golar LNG Limited announced that FLNG Gimi received feed gas from the bp-operated FPSO on the Greater Tortue Ahmeyim (GTA) project offshore Mauritania and Senegal. Full commissioning of the FLNG has ...

BP announced on Thursday that it will cut around 4,700 staff, or over 5 per cent of its total workforce, as part of CEO Murray Auchincloss' efforts to reduce costs. BP told staff that 3,000 contractor ...

BP will slash over 5% of its global workforce as part of CEO Murray Auchincloss’ efforts to reduce costs and rebuild investor confidence after the energy giant was rocked by scandal, the company ...

BP is planning to cut more than 5% of its 90,000-strong workforce as part of a cost-cutting drive. The British oil giant told employees in a memo Thursday that it would slash around 4,700 jobs ...

Copyright 2025 The Associated Press. All Rights Reserved. A logo of BP at a gas station in London, on Nov. 1, 2022. (AP Photo/Kin Cheung, File) Updated [hour]:[minute ...

BP has announced it is cutting 4,700 jobs from its global workforce. The energy giant also said it will cut 3,000 contractor roles as part of a cost-saving drive across the company. It comes as ...

BP shares rose 1.4% to 428.8 pence on Thursday in London trading. BP’s fall in recent years reflects strategic miscalculations that extend far beyond Auchincloss’s single year as permanent CEO.

The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...